CRISPR Therapeutics (CRSP) has released its third quarter 2026 results, reporting revenue of US$12.67 million and a net loss of US$111.44 million, providing investors with updated financial data to review.
The latest quarterly update and pipeline news landed against a backdrop where CRISPR Therapeutics' share price has eased 9.81% over the past 30 days and 7.03% year to date, while its 1 year total shareholder return has declined 19.33%. This signals fading momentum despite recent clinical and leadership milestones.
Spot opportunities beyond CRISPR Therapeutics by scanning a hand picked 33 healthcare AI stocks that could benefit from the same interest in advanced genetic and RNA based therapies.
CRISPR Therapeutics now trades at a steep discount to both analyst targets and one intrinsic value estimate after its latest slide. Is that a margin of safety, or a warning that the market's caution is warranted?
Most Popular Narrative: 43% Undervalued
Against a last close of $49.99, the most followed narrative for CRISPR Therapeutics points to a fair value of about $87.56, implying a sizeable gap that hinges on successful execution of its late stage pipeline.
The main requirement for success is effective late-stage clinical execution for CTX310, CTX611, and zugo-cel, alongside managing competition and funding increased trial spending from the current cash base and new financing tools.
The current valuation implies that the market is not fully pricing in the potential of CASGEVY to reach multibillion dollar sales, in addition to possible long-term contributions from cardiometabolic, autoimmune, and hematology programs.
See why 14 investors see CRISPR Therapeutics as 43% undervalued .
Result: Fair Value of $87.56 (UNDERVALUED)
Still, CRISPR Therapeutics carries clear pressure points, including ongoing quarterly losses and potential dilution from its US$600 million in convertible notes and shelf registration activity.
Find out about the key risks to this CRISPR Therapeutics narrative .
Next Steps
Sentiment across CRISPR Therapeutics is clearly mixed, with risks and upside sitting side by side, so it pays to review the underlying data yourself and move early while the information is fresh. To see what the optimism is built on, check out the 2 key rewards
Looking for more ideas beyond CRISPR Therapeutics?
If you want a broader view of opportunities, use the Simply Wall St screener to find other stocks that fit the kind of portfolio you are building.
-
Target resilient performers by checking a 29 resilient stocks with low risk scores that aims to keep overall portfolio volatility in check.
-
Hunt for mispriced opportunities through a focused 34 high quality undervalued stocks that highlights companies with strong fundamentals at compressed valuations.
-
Strengthen your income stream with a curated 4 dividend fortresses that concentrates on higher yielding payers with meaningful distributions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CRSP .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
